Renowned physician‑scientist to lead Houston Methodist’s cell and gene therapy research
Malcolm Brenner, a physician-scientist and member of the National Academy of Medicine, will lead the new Houston Methodist Center for Cell and Gene Therapy. According to Houston Methodist, the center aims to accelerate the translation of pre-clinical discoveries into clinical treatments for various congenital and acquired diseases.
The center’s primary objective is to unite scientists and clinicians across Houston Methodist’s academic research and clinical care settings. This collaborative structure is designed to discover and advance new therapies for a wide range of conditions.
What is the goal of the Houston Methodist Center for Cell and Gene Therapy?
The center will support the development of both genetic and cellular therapies to address conditions throughout the body. By uniting expertise across disciplines, the facility intends to move promising pre-clinical discoveries into clinical evaluation more quickly.
Jenny Chang, president and CEO of the Houston Methodist Academic Institute, stated that Brenner is a pioneer in the field and uniquely qualified for the role. Chang noted that his leadership will play a “pivotal role” in advancing the organization’s work in this space.
Who is Malcolm Brenner?
Brenner is a professor of pediatrics, medicine, molecular and human genetics, and translational biology at Baylor College of Medicine. He was trained as a physician-scientist in immunology and hematology.
His research helped redefine bone marrow transplantation as a form of cell therapy. He was also among the first to demonstrate that engineered immune cells could effectively and safely treat cancer and infection.
Brenner’s work established the clinical potential of gene-modified hematopoietic stem cells and virus-specific T cells. These contributions helped create therapies that provide durable or lifelong benefits for patients.
What happens next for the center’s research?
The center will house a team of support staff, physician-scientists, and translational research scientists. Brenner and his team may continue their long-term collaborations with Texas Children’s Hospital and Baylor College of Medicine.
Because Brenner helped architect early standards for how complex therapies are regulated and delivered, the center could implement these global infrastructure standards in its new clinical evaluations.
Frequently Asked Questions
What types of conditions will the center address?
The center is designed to develop genetic and cellular therapies for both acquired and congenital conditions throughout the body.
What are Malcolm Brenner’s professional affiliations?
Brenner is a professor at Baylor College of Medicine and is elected to the National Academy of Inventors and the National Academy of Medicine.
How will the center accelerate therapy development?
It will use a collaborative approach that unites clinicians and scientists across academic research and clinical care settings to move pre-clinical discoveries into clinical evaluation.
How do you think the integration of academic research and clinical care will change the speed of medical breakthroughs?